1.      Abdel Razek AA, Abd El-Gaber N, Abdalla A, et al. Apparent diffusion coefficient vale of the brain in patients with Gaucher's disease type II and type III. Neuroradiology. 2009;51(11):773-779. doi:10.1007/s00234-009-0548-1

2.      Adachi M, Schneck L, Cara J, et al. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol. 1973;4(3):331-347. doi:10.1016/s0046-8177(73)80098-x

3.      Ah Mew N, Krivitzky L, McCarter R, et al. Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. J Pediatr. 2013;162(2):324-9.e1. doi:10.1016/j.jpeds.2012.06.065

4.      Alanghat S, Matthai J, Marimuthu V, et al. Biotinidase Deficiency Presenting as Recurrent Laryngeal Stridor. Indian J Pediatr. 2021;88(6):617-618. doi:10.1007/s12098-020-03635-y

5.      Alfadhel M, Nashabat M, Qahtani HA, et al. Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016;135(11):1263-1268. doi:10.1007/s00439-016-1719-x

6.      Benussi A, Cotelli MS, Padovani A, et al. Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. F1000Res. 2018;7:194. Published 2018 Feb 15. doi:10.12688/f1000research.12361.1

7.      Biswas A, Krishnan P, Amirabadi A, et al. Expanding the Neuroimaging Phenotype of Neuronal Ceroid Lipofuscinoses. AJNR Am J Neuroradiol. 2020;41(10):1930-1936. doi:10.3174/ajnr.A6726

8.      Biswas A, McNamara C, Gowda VK, et al. Neuroimaging Features of Biotinidase Deficiency. AJNR Am J Neuroradiol. 2023;44(3):328-333. doi:10.3174/ajnr.A7781

9.      Bongarzone ER, Escolar ML, Gray SJ, et al. Insights into the Pathogenesis and Treatment of Krabbe Disease. Pediatr Endocrinol Rev. 2016;13 Suppl 1:689-696.

10.  Boy N, Heringer J, Brackmann R, et al. Extrastriatal changes in patients with late-onset glutaric aciduria type I highlight the risk of long-term neurotoxicity. Orphanet J Rare Dis. 2017;12(1):77. Published 2017 Apr 24. doi:10.1186/s13023-017-0612-6

11.  Boy N, Mengler K, Heringer-Seifert J, et al. Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis. Genet Med. 2021;23(1):13-21. doi:10.1038/s41436-020-00971-4

12.  Boy N, Mühlhausen C, Maier EM, et al. Recommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision. J Inherit Metab Dis. 2023;46(3):482-519. doi:10.1002/jimd.12566

13.  Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013;36(4):595-612. doi:10.1007/s10545-012-9546-2

14.  Braissant O. Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:S3-S12. doi:10.1016/j.ymgme.2010.02.010

15.  Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016;117(3):313-321. doi:10.1016/j.ymgme.2015.12.009

16.  Brismar J, Brismar G, Gascon G, et al. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol. 1990;11(4):805-810.

17.  Chang SC, Eichinger CS, Field P. The natural history and burden of illness of metachromatic leukodystrophy: a systematic literature review. Eur J Med Res. 2024;29(1):181. Published 2024 Mar 18. doi:10.1186/s40001-024-01771-1

18.  Cordeiro D, Bullivant G, Siriwardena K, et al. Genetic landscape of pediatric movement disorders and management implications. Neurol Genet. 2018;4(5):e265. Published 2018 Sep 26. doi:10.1212/NXG.0000000000000265

19.  D'Souza P, Farmer C, Johnston JM, et al. GM1 gangliosidosis type II: Results of a 10-year prospective study. Genet Med. 2024;26(7):101144. doi:10.1016/j.gim.2024.101144

20.  Davis RL, Liang C, Sue CM. Mitochondrial diseases. Handb Clin Neurol. 2018;147:125-141. doi:10.1016/B978-0-444-63233-3.00010-5

21.  De Grandis E, Di Rocco M, Pessagno A, et al. MR imaging findings in 2 cases of late infantile GM1 gangliosidosis. AJNR Am J Neuroradiol. 2009;30(7):1325-1327. doi:10.3174/ajnr.A1508

22.  De Meirleir L, Rodan LH. Approach to the Patient with a Metabolic Disorder. In: Swaiman KF, Ashwal S, Ferriero DM, et al, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 6th ed. Elsevier; 2017:2077-2085.

23.  Engelen M, Kemp S, Poll-The BT. X-linked adrenoleukodystrophy: pathogenesis and treatment. Curr Neurol Neurosci Rep. 2014;14(10):486. doi:10.1007/s11910-014-0486-0

24.  Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J Inherit Metab Dis. 2021;44(3):566-592. doi:10.1002/jimd.12370

25.  Francisco R, Brasil S, Poejo J, et al. Congenital disorders of glycosylation (CDG): state of the art in 2022. Orphanet J Rare Dis. 2023;18(1):329. Published 2023 Oct 19. doi:10.1186/s13023-023-02879-z

26.  Fridovich-Keil JL, Berry GT. Pathophysiology of long-term complications in classic galactosemia: What we do and do not know. Mol Genet Metab. 2022;137(1-2):33-39. doi:10.1016/j.ymgme.2022.07.005

27.  Gagneux P, Hennet T, Varki A. Biological Functions of Glycans. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology. 4th ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022.79-92.

28.  Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1-2):49-61. doi:10.1016/j.ymgme.2022.07.010

29.  Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080. Published 2016 Oct 20. doi:10.1038/nrdp.2016.80

30.  Gowda VK, Vignesh S, Nagarajan B, et al. Rare Treatable Cause of Demyelinating Leukoencephalopathy That One Cannot Afford to Miss. J Pediatr Genet. 2020;11(2):87-90. Published 2020 Dec 18. doi:10.1055/s-0040-1721678

31.  Gümüş E, Özen H. Glycogen storage diseases: An update. World J Gastroenterol. 2023;29(25):3932-3963. doi:10.3748/wjg.v29.i25.3932

32.  He W, Wu G. Metabolism of Amino Acids in the Brain and Their Roles in Regulating Food Intake. Adv Exp Med Biol. 2020;1265:167-185. doi:10.1007/978-3-030-45328-2_10

33.  Hoover-Fong JE, Shah S, Van Hove JL,et al. Natural history of nonketotic hyperglycinemia in 65 patients. Neurology. 2004;63(10):1847-1853. doi:10.1212/01.wnl.0000144270.83080.29

34.  Hoshino H, Kubota M. Canavan disease: clinical features and recent advances in research. Pediatr Int. 2014;56(4):477-483. doi:10.1111/ped.12422

35.  Iqbal M, Prasad M, Mordekar SR. Nonketotic hyperglycinemia case series. J Pediatr Neurosci. 2015;10(4):355-358. doi:10.4103/1817-1745.174445

36.  Jain A, Jagdeesh K, Mane R, et al. Imaging in classic form of maple syrup urine disease: a rare metabolic central nervous system. J Clin Neonatol. 2013;2(2):98-100. doi:10.4103/2249-4847.116411

37.  Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822(9):1465-1474. doi:10.1016/j.bbadis.2012.03.012

38.  Kern J, Böhringer J, Timmann D, et al. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of Onset. Neurology. 2024;102(1):e207898. doi:10.1212/WNL.0000000000207898

39.  Kölker S, Sauer SW, Hoffmann GF, et al. Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism. J Inherit Metab Dis. 2008;31(2):194-204. doi:10.1007/s10545-008-0823-z

40.  Lake NJ, Compton AG, Rahman S, et al. Leigh syndrome: One disorder, more than 75 monogenic causes. Ann Neurol. 2016;79(2):190-203. doi:10.1002/ana.24551

41.  Lefeber DJ, Freeze HH, Steet R, et al. Congenital Disorders of Glycosylation. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology. 4th ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2022.599-614.

42.  Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis. 2021;44(3):728-739. doi:10.1002/jimd.12356

43.  Mardhiah M, Azize NAA, Yakob Y, et al. Clinical, biochemical and mutational findings in biotinidase deficiency among Malaysian population. Mol Genet Metab Rep. 2019;22:100548. Published 2019 Dec 19. doi:10.1016/j.ymgmr.2019.100548

44.  Maresca G, Formica C, Nocito V, et al. Neuropsychological assessment in Niemann-Pick disease type C: a systematic review. Neurol Sci. 2021;42(8):3167-3175. doi:10.1007/s10072-021-05337-5

45.  Mayr SJ, Sass JO, Vry J, et al. A mild case of molybdenum cofactor deficiency defines an alternative route of MOCS1 protein maturation. J Inherit Metab Dis. 2018;41(2):187-196. doi:10.1007/s10545-018-0138-7

46.  Misko AL, Liang Y, Kohl JB, et al. Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet. 2020;6(4):e486. Published 2020 Jul 14. doi:10.1212/NXG.0000000000000486

47.  Morton DH, Strauss KA, Robinson DL, et al. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002;109(6):999-1008. doi:10.1542/peds.109.6.999

48.  Muthusamy K, Sudhakar SV, Thomas M, et al. Revisiting magnetic resonance imaging pattern of Krabbe disease - Lessons from an Indian cohort. J Clin Imaging Sci. 2019;9:25. Published 2019 May 24. doi:10.25259/JCIS-18-2019

49.  Nestrasil I, Ahmed A, Utz JM, et al. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study. Mol Genet Metab. 2018;123(2):97-104. doi:10.1016/j.ymgme.2017.12.432

50.  Nguyen HV, Ishak GE. Canavan disease - unusual imaging features in a child with mild clinical presentation. Pediatr Radiol. 2015;45(3):457-460. doi:10.1007/s00247-014-3116-8

51.  Nicoli ER, Annunziata I, d'Azzo A, et al. GM1 Gangliosidosis-A Mini-Review. Front Genet. 2021;12:734878. Published 2021 Sep 3. doi:10.3389/fgene.2021.734878

52.  Orsini JJ, Escolar ML, Wasserstein MP, et al. Krabbe Disease. 2000 Jun 19 [Updated 2018 Oct 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1238/

53.  Patterson MC. Disease Associated With Primary Abnormalities in Carbohydrate Metabolism. In: Swaiman KF, Ashwal S, Ferriero DM, et al, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 7th ed. Elsevier; 2025:539-557.

54.  Perucca G, Soares BP, Staglianò S, et al. Thalamic and dentate nucleus abnormalities in the brain of children with Gaucher disease. Neuroradiology. 2018;60(12):1353-1356. doi:10.1007/s00234-018-2116-z

55.  Piedade A, Francisco R, Jaeken J, et al. Epidemiology of congenital disorders of glycosylation (CDG): overview and perspectives. Journal of Rare Diseases. 2022;1(1):3. doi:10.1007/s44162-022-00003-6.

56.  Pintor J. Sugars, the crystalline lens and the development of cataracts. Biochem Pharmacol (Open Access). 2012;1(4):1000e119. doi:10.4172/2167-0501.1000e119.

57.  Platt FM, d'Azzo A, Davidson BL, et al. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27. Published 2018 Oct 1. doi:10.1038/s41572-018-0025-4

58.  Raymond GV, Baranano KW, Wangler MF, et al. Peroxisomal Disorders. In: Ashwal S, Pearl PL, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 7th ed. Elsevier; 2025:607-613.e2.

59.  Rosenberg JB, Chen A, Kaminsky SM, et al. Advances in the Treatment of Neuronal Ceroid Lipofuscinosis. Expert Opin Orphan Drugs. 2019;7(11):473-500. doi:10.1080/21678707.2019.1684258

60.  Rossi-Espagnet MC, Sudhakar S, Fontana E, et al. Neuroradiologic Phenotyping of Galactosemia: From the Neonatal Form to the Chronic Stage. AJNR Am J Neuroradiol. 2021;42(3):590-596. doi:10.3174/ajnr.A7016

61.  Scelsa B, Gasperini S, Righini A, et al. Mild phenotype in Molybdenum cofactor deficiency: A new patient and review of the literature. Mol Genet Genomic Med. 2019;7(6):e657. doi:10.1002/mgg3.657

62.  Schiffmann R. Fabry disease. Handb Clin Neurol. 2015;132:231-248. doi:10.1016/B978-0-444-62702-5.00017-2

63.  Schwahn BC, Sinha R, Wright JAM, et al. Brain Magnetic Resonance Imaging of Children With Molybdenum Cofactor Deficiency. J Inherit Metab Dis. 2025;48(5):e70079. doi:10.1002/jimd.70079

64.  Sen K, Lichter-Konecki U. Urea Cycle Disorders. In: Swaiman KF, Ashwal S, Ferriero DM, et al, eds. Swaiman’s Pediatric Neurology: Principles and Practice. 7th ed. Elsevier; 2025:530-538.

65.  Sen K, Whitehead M, Castillo Pinto C, et al. Fifteen years of urea cycle disorders brain research: Looking back, looking forward. Anal Biochem. 2022;636:114343. doi:10.1016/j.ab.2021.114343.

66.  Shaimardanova AA, Solovyeva VV, Issa SS, et al. Gene Therapy of Sphingolipid Metabolic Disorders. Int J Mol Sci. 2023;24(4):3627. Published 2023 Feb 11. doi:10.3390/ijms24043627

67.  Simon E, Flaschker N, Schadewaldt P, et al. Variant maple syrup urine disease (MSUD)--the entire spectrum. J Inherit Metab Dis. 2006;29(6):716-724. doi:10.1007/s10545-006-0276-1

68.  Sperry E, Leslie N, Berry L, et al. Pompe Disease. 2007 Aug 31 [Updated 2025 Aug 21]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1261/

69.  Stence NV, Fenton LZ, Levek C, et al. Brain imaging in classic nonketotic hyperglycinemia: Quantitative analysis and relation to phenotype. J Inherit Metab Dis. 2019;42(3):438-450. doi:10.1002/jimd.12072

70.  Stirnemann J, Belmatoug N, Camou F, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2):441. Published 2017 Feb 17. doi:10.3390/ijms18020441

71.  Strauss KA, Carson VJ, Soltys K, et al. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Mol Genet Metab. 2020;129(3):193-206. doi:10.1016/j.ymgme.2020.01.006

72.  Strauss KA, Puffenberger EG, Carson VJ. Maple Syrup Urine Disease. 2006 Jan 30 [Updated 2020 Apr 23]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1319/

73.  Summar ML, Mew NA. Inborn Errors of Metabolism with Hyperammonemia: Urea Cycle Defects and Related Disorders. Pediatr Clin North Am. 2018;65(2):231-246. doi:10.1016/j.pcl.2017.11.004

74.  Surendran S, Bamforth FJ, Chan A, et al. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem. J Child Neurol. 2003;18(11):809-812. doi:10.1177/08830738030180111601

75.  Tabarki B, Ortigoza-Escobar JD, Lee WT, et al. Editorial: Pediatric Neurometabolic Disorders. Front Neurol. 2021;12:737398. Published 2021 Sep 7. doi:10.3389/fneur.2021.737398

76.  Tan WH, Eichler FS, Hoda S, et al. Isolated sulfite oxidase deficiency: a case report with a novel mutation and review of the literature. Pediatrics. 2005;116(3):757-766. doi:10.1542/peds.2004-1897

77.  Tankeu AT, Van Winckel G, Elmers J, et al. Biotinidase deficiency: What have we learned in forty years?. Mol Genet Metab. 2023;138(4):107560. doi:10.1016/j.ymgme.2023.107560

78.  Timson DJ. Type IV galactosemia. Genet Med. 2019;21(6):1283-1285. doi:10.1038/s41436-018-0359-z

79.  Toro C, Zainab M, Tifft CJ. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment. Neurosci Lett. 2021;764:136195. doi:10.1016/j.neulet.2021.136195

80.  Traeger EC, Rapin I. The clinical course of Canavan disease. Pediatr Neurol. 1998;18(3):207-212. doi:10.1016/s0887-8994(97)00185-9

81.  Turk BR, Theda C, Fatemi A, et al. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52-72. doi:10.1002/jdn.10003

82.  van Capelle CI, van der Meijden JC, van den Hout JM, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis. 2016;11(1):65. Published 2016 May 18. doi:10.1186/s13023-016-0442-y

83.  van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: Disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab. 2015;29(2):261-273. doi:10.1016/j.beem.2014.10.001

84.  Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-200. doi:10.1038/gim.2013.157

85.  Wastell HJ, Bartlett K, Dale G, et al. Biotinidase deficiency: a survey of 10 cases. Arch Dis Child. 1988;63(10):1244-1249. doi:10.1136/adc.63.10.1244

86.  Wei H, Moffett JR, Amanat M, et al. The pathogenesis of, and pharmacological treatment for, Canavan disease. Drug Discov Today. 2022;27(9):2467-2483. doi:10.1016/j.drudis.2022.05.019

87.  Zhang X, Vincent AS, Halliwell B, et al. A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase. J Biol Chem. 2004;279(41):43035-43045. doi:10.1074/jbc.M402759200